Structure-Based Drug Design

The use of X-ray crystallography and molecular modeling to understand enzyme-inhibitor binding interactions can dramatically accelerate the process of optimizing early lead compounds, transforming them from leads with weak activities into highly potent, and selective, clinical candidates.  Whenever possible, we incorporate these technologies in our drug discovery collaborations in order to maximize our effectiveness.

  • Protein production and purification
  • X-ray crystallography of small molecule inhibitors bound to protein targets
  • Molecular modeling for lead optimization
  • Biophysical analysis of protein-inhibitor interactions